LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Slēgts

3.41 3.02

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.41

Max

3.41

Galvenie mērījumi
By Trading Economics
Ienākumi	5.5M -28M
Pārdošana	8.2M 13M
Peļņas marža	-208.694
Darbinieki	172
EBITDA	8.7M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+339.26% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 10. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-66M 188M
Iepriekšējā atvēršanas cena	0.39
Iepriekšējā slēgšanas cena	3.41

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 22. febr. 23:55 UTC

Tirgus saruna

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

2026. g. 22. febr. 23:53 UTC

Tirgus saruna

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

2026. g. 22. febr. 23:53 UTC

Tirgus saruna

Key China Rates Likely to Be Held Steady for Now -- Market Talk

2026. g. 22. febr. 23:51 UTC

Tirgus saruna

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

2026. g. 22. febr. 23:35 UTC

Tirgus saruna

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

2026. g. 22. febr. 23:21 UTC

Peļņas

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

2026. g. 22. febr. 23:20 UTC

Peļņas

Nickel Industries 2025 Operating Profit US$126.4 Million

2026. g. 22. febr. 23:19 UTC

Peļņas

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

2026. g. 22. febr. 23:19 UTC

Peļņas

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

2026. g. 22. febr. 23:18 UTC

Peļņas

Nickel Industries Won't Pay a Final Dividend

2026. g. 22. febr. 23:16 UTC

Peļņas

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

2026. g. 22. febr. 21:35 UTC

Peļņas

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

2026. g. 22. febr. 21:34 UTC

Peļņas

Ampol Says F&I Australia, International Have Begun 2026 Strongly

2026. g. 22. febr. 21:34 UTC

Peļņas

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

2026. g. 22. febr. 21:33 UTC

Peļņas

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

2026. g. 22. febr. 21:33 UTC

Peļņas

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

2026. g. 22. febr. 21:28 UTC

Peļņas

Ampol Final Dividend A$0.60/Share

2026. g. 22. febr. 21:28 UTC

Peļņas

Ampol FY Revenue A$31.37 Billion, Down 10%

2026. g. 22. febr. 21:28 UTC

Peļņas

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

2026. g. 22. febr. 21:28 UTC

Peļņas

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

2026. g. 21. febr. 14:31 UTC

Iegādes, apvienošanās, pārņemšana

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

2026. g. 21. febr. 05:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 20. febr. 23:12 UTC

Iegādes, apvienošanās, pārņemšana

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

2026. g. 20. febr. 22:12 UTC

Peļņas

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

2026. g. 20. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 20. febr. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 20. febr. 21:23 UTC

Peļņas

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

2026. g. 20. febr. 21:20 UTC

Tirgus saruna

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

2026. g. 20. febr. 21:01 UTC

Iegādes, apvienošanās, pārņemšana

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

2026. g. 20. febr. 20:38 UTC

Tirgus saruna

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

339.26% augšup

Prognoze 12 mēnešiem

Vidējais 15.33 USD 339.26%

Augstākais 25 USD

Zemākais 10 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.